Literature DB >> 17631906

The role of preexisting pathology in the development of neointimal hyperplasia in coronary artery bypass grafts.

Zachary N Kon1, Charles White, Michael H Kwon, Jean Judy, Emile N Brown, Junyan Gu, Nicholas S Burris, Patrick C Laird, Talitha Brown, Phillip S Brazio, James Gammie, James Brown, Bartley P Griffith, Robert S Poston.   

Abstract

OBJECTIVE: Saphenous vein grafts (SVG) used for coronary artery bypass surgery (CABG) often develop a gradual luminal narrowing over the first year due to neointimal hyperplasia (NH). Although the basic science of NH is well studied, our clinical understanding of this issue is limited. The purpose of this cohort study was to investigate clinical risk factors for NH by monitoring luminal narrowing within SVG using multichannel CT angiography (CTA).
METHODS: Thirty patients underwent CABG involving SVG (N = 44) and arterial grafts (N = 36). Patient variables were recorded and the baseline quality of each conduit determined intraoperatively by analyzing surplus segments for intima-media thickness ratio (IMT) by histology and matrix metalloproteinase-2 by enzyme-linked immunosorbent assay. Percent luminal narrowing (%LN) was calculated for each patent graft by comparing the CTA appearance on day 5 to a repeat study at 1 y.
RESULTS: Compared with arterial grafts, SVG showed significantly higher IMT at baseline (0.9 +/- 0.65 versus 0.22 +/- 0.17, P < 0.0001) and more %LN over the first year (6.9 +/- 7.5 versus 25.3 +/- 13.3% LN, P< 0.0001). Of all of the measured variables, the only significant predictors of %LN included baseline IMT (r = 0.58, P = 0.002) and matrix metalloproteinase-2 levels (r = 0.60, P = 0.002) in SVG.
CONCLUSIONS: The degree of NH at baseline, a phenomenon exclusive to SVG and not found in arterial grafts, was significantly related to the development of lumen loss in the conduit over the first year after CABG. The study of SVG using serial CTA may provide unique insights into the natural history of SVG remodeling and to identify factors that influence the long-term function of this conduit.

Entities:  

Mesh:

Year:  2007        PMID: 17631906      PMCID: PMC4146434          DOI: 10.1016/j.jss.2007.03.062

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  21 in total

1.  Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.

Authors:  A Ehsan; M J Mann; G Dell'Acqua; V J Dzau
Journal:  J Thorac Cardiovasc Surg       Date:  2001-04       Impact factor: 5.209

2.  Cyclic strain-induced endothelial MMP-2: role in vascular smooth muscle cell migration.

Authors:  Nicholas von Offenberg Sweeney; Philip M Cummins; Yvonne A Birney; Eileen M Redmond; Paul A Cahill
Journal:  Biochem Biophys Res Commun       Date:  2004-07-23       Impact factor: 3.575

3.  Non-invasive assessment of coronary artery bypass graft with retrospectively ECG-gated four-row multi-detector spiral computed tomography.

Authors:  Riccardo Marano; Maria Luigia Storto; Nicola Maddestra; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2004-04-22       Impact factor: 5.315

4.  The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells.

Authors:  H Uzui; J D Lee; H Shimizu; H Tsutani; T Ueda
Journal:  Atherosclerosis       Date:  2000-03       Impact factor: 5.162

5.  Catheter-based infrared light scanner as a tool to assess conduit quality in coronary artery bypass surgery.

Authors:  Nicholas Burris; Kimberly Schwartz; Cha-Min Tang; M Samir Jafri; Joseph Schmitt; Michael H Kwon; Ozeki Toshinaga; Junyan Gu; Jamie Brown; Emile Brown; Richard Pierson; Robert Poston
Journal:  J Thorac Cardiovasc Surg       Date:  2006-12-29       Impact factor: 5.209

6.  Histological survey of the saphenous vein before its use as autologous aortocoronary bypass graft.

Authors:  G Thiene; P Miazzi; M Valsecchi; M Valente; U Bortolotti; D Casarotto; V Gallucci
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

7.  Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.

Authors:  L Cashin-Hemphill; W J Mack; J M Pogoda; M E Sanmarco; S P Azen; D H Blankenhorn
Journal:  JAMA       Date:  1990-12-19       Impact factor: 56.272

Review 8.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

9.  Kinetics of vein graft hyperplasia: association with tangential stress.

Authors:  R M Zwolak; M C Adams; A W Clowes
Journal:  J Vasc Surg       Date:  1987-01       Impact factor: 4.268

10.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

View more
  3 in total

Review 1.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

2.  Vascular restenosis in coronary artery bypass grafting might be associated with VEGF-C/VEGFR-3 signaling pathway.

Authors:  Zuzanna Podemska-Jedrzejczak; Agnieszka Malinska; Patrycja Sujka-Kordowska; Michal Nowicki; Mateusz Puslecki; Marek Jemielity; Bartlomiej Perek
Journal:  Heart Vessels       Date:  2018-03-20       Impact factor: 2.037

Review 3.  The Role of Immunomodulation in Vein Graft Remodeling and Failure.

Authors:  Fabiana Baganha; Alwin de Jong; J Wouter Jukema; Paul H A Quax; Margreet R de Vries
Journal:  J Cardiovasc Transl Res       Date:  2020-06-16       Impact factor: 4.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.